• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Diagnosis of nonalcoholic fatty liver disease (NAFLD).

作者信息

Yki-Järvinen Hannele

出版信息

Duodecim. 2016;132(22):2099-106.

PMID:29190058
Abstract

Nonalcoholic fatty liver disease (NAFLD) increases mortality from liver and heart disease and is the most important cause of hepatocellular carcinoma (HCC), which is rapidly becoming more common. Those having an increased fibrosis risk, cirrhosis or HCC should be identified amongst those with simple steatosis. Liver enzymes should always be determined at the yearly follow-up of patients with type 2 diabetes and those with the metabolic syndrome. Fatty liver should lead to an assessment of the risk of fibrosis by using a simple fibrosis test and to the referral of patients at risk by a specialist for diagnosis and treatment of NASH and fibrosis. NASH can only be diagnosed using a liver biopsy.

摘要

相似文献

1
Diagnosis of nonalcoholic fatty liver disease (NAFLD).
Duodecim. 2016;132(22):2099-106.
2
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的组织病理学
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
3
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.利用动物模型研究非酒精性脂肪性肝炎相关的肝细胞癌。
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
4
Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.非酒精性脂肪性肝病的无创评估:当前证据与实践
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326. doi: 10.3748/wjg.v25.i11.1307.
5
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.非肝硬化非酒精性脂肪性肝病(NAFLD)患者肝细胞癌(HCC)的特征
Hepatol Int. 2016 Jul;10(4):632-9. doi: 10.1007/s12072-015-9679-0. Epub 2015 Nov 11.
6
Clinical relevance of liver histopathology and different histological classifications of NASH in adults.成人非酒精性脂肪性肝炎的肝脏组织病理学和不同组织学分类的临床相关性。
Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):351-367. doi: 10.1080/17474124.2018.1415756. Epub 2017 Dec 26.
7
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.退伍军人事务部经活检证实的非酒精性脂肪性肝病进展的危险因素。
Aliment Pharmacol Ther. 2018 Jan;47(2):268-278. doi: 10.1111/apt.14411. Epub 2017 Nov 8.
8
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.非肝硬化非酒精性脂肪性肝病和代谢综合征背景下的肝细胞癌:美国的经验
Dig Dis Sci. 2015 Oct;60(10):3142-8. doi: 10.1007/s10620-015-3821-7. Epub 2015 Aug 7.
9
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
10
Managing non-alcoholic fatty liver disease.非酒精性脂肪性肝病的管理
Singapore Med J. 2016 Jul;57(7):368-71. doi: 10.11622/smedj.2016119.

引用本文的文献

1
The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation.转录因子 CREBH、PPARa 和 FOXO1 作为饮食诱导代谢失调的关键肝内调节介质。
J Nutr Biochem. 2021 Sep;95:108633. doi: 10.1016/j.jnutbio.2021.108633. Epub 2021 Mar 28.
2
Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat.决明子乙醇提取物对实验性大鼠非酒精性脂肪肝病的保护作用。
Pharm Biol. 2019 Dec;57(1):98-104. doi: 10.1080/13880209.2019.1568509.